The CTAD conference featured discussion among many scientists of how to measure a drug’s effect in pre-dementia patients who are so mildly impaired that established tools have trouble picking up improvement. Better cognitive tools are needed.
Both antibodies might be working, experts say, but the latest data released at the CTAD conference remain tantalizingly unclear. Trialists urgently need progression predictors and better outcome measures.
In a process known as repeat-associated non-ATG translation, neurons and glia make alanine, serine, cysteine, and leucine chains from the huntingtin gene.
Paralyzed mice recovered grip strength and balance when researchers turned off TDP-43.
Meet RBM45. This RNA-binding protein and relatively new player in the ALS field associates with stress-induced structures in the cytoplasm and nucleus.
Scientists say treatments to muzzle faulty genes are making some headway.
Scientists at SfN offer alternate views of Bin1 biology.
Scientists start to unravel role played by genetic risk variants.
Two drugs that boost α-synuclein clearance have passed Phase 1 safety benchmarks, and a stem cell strategy is poised to enter trials, reported scientists at SfN 2015.
Researchers at SfN 2015 outlined perinatal treatments that rescued cognition in mouse models of the disease.
The RNA-binding protein hnRNP A3 can help rid a cell of the repeat RNAs, but the RNAs interfere with its nuclear localization.
Research presented at SfN strengthens the case that microglia gorge on synapses in some neurodegenerative and neurodevelopmental disorders.
The ALS-linked RNA may convert free-floating proteins to liquid phase droplets.
Phenotypes vary depending on the partial or full-length nature of the C9ORF72 transgene.
Basic science inspires conference goers in Chicago.